SNDXSyndax Pharmaceuticals Inc

Syndax Pharmaceuticals (NASDAQ:SNDX) just posted a quarter that nearly doubled revenue, yet shares slipped 2.41% anyway. On its August 4 earnings call, management reported combined sales of $115 million across its two approved drugs, both now annualizing above $200 million a year. So why didn’t the market cheer? The answer sits inside the details investors […]

Revenue surged 92% year-over-year to $72.8 million, driven by Revuforj and Niktimvo.

Syndax Pharmaceuticals reported past second-quarter 2026 results with revenue rising to US$72.79 million from US$37.96 million, while net loss narrowed to US$49.36 million and basic loss per share improved to US$0.55 from US$0.83 a year earlier. An interesting takeaway is that six‑month revenue more than doubled to US$137.65 million as losses shrank materially, suggesting improving operating leverage as Revuforj and Niktimvo sales scale. We’ll now explore how this revenue acceleration and...

Syndax Pharmaceuticals Inc (SNDX) reports strong Q2 2026 results with combined product revenue reaching $115 million, despite fluctuations in new patient starts.

Syndax Pharmaceuticals (NASDAQ:SNDX) reported second-quarter 2026 total revenue of $72.8 million, up 92% from the prior-year period, as sales of its leukemia treatment Revuforj and chronic graft-versus-host disease therapy Niktimvo continued to grow. Chief Executive Officer Michael Metzger said the

Syndax (SNDX) delivered earnings and revenue surprises of -22.22% and -11.16%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Harmony Biosciences (HRMY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Does Syndax Pharmaceuticals (SNDX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Syndax Pharmaceuticals (NASDAQ:SNDX) used a company R&D event to outline expansion plans for its approved medicines Revuforj and Niktimvo while introducing two pipeline assets aimed at non-small cell lung cancer and myelofibrosis. Chief Executive Officer Michael Metzger said the company is now

The consensus price target hints at a 70.4% upside potential for Syndax (SNDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.